In a matter involving alleged abuse of the U.S. Pharmacopeia standard setting process, CRA examined market power for product dispensed through hospital and non-hospital sites of care. CRA’s expert found that in most uses, during the relevant time period there was ample evidence of competition, finding that the manufacturer at issue was effectively price constrained by existing competition.
CRA strengthens its Antitrust & Competition Economics Practice
“We are pleased to welcome Nate to CRA’s Antitrust & Competition Economics Practice,” said Paul Maleh, President and Chief Executive Officer of Charles River...